Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

BIO/SECL/SP/2023-24/120

November 17, 2023

To, The Secretary **BSE Limited** Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001	To, The Secretary **National Stock Exchange of India Limited** Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050
Scrip Code - 532523	**Scrip Symbol- BIOCON**

Dear Sir/Madam,

Subject: Investor Presentation – Q2 FY24.

With reference to the captioned subject, please find enclosed the Investor Presentation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations").

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the above said information on record.

Thanking You,

Yours faithfully,

For **Biocon Limited**

MAYANK VERMA
Digitally signed by MAYANK VERMA
Date: 2023.11.17 18:23:26 +05'30'

Mayank Verma
Company Secretary & Compliance Officer
Membership No.: ACS 18776

Encl.: Investor Presentation

Q2 FY24 Investor Presentation

November 2023

Relentless Pursuit.
Differentiated Growth.

Biocon is a technology-enabled, future-ready, global biopharmaceuticals leader driven by an unwavering purpose to enhance healthcare worldwide through high-quality, affordable therapies that can lower costs, increase access and improve treatment outcomes.





Building Biocon

Biocon at a Glance

₹11,550 Cr | $ ~1.4 bn
Revenue*

~16,500+
Total Employees*

Rank #8
Among Top 10 Global Biotech, Pharma & Biopharma Sector**

1,500+
Patents*

100+
cGMP approvals from International regulatory agencies

8
Manufacturing units*

120+
Countries where our products are available*

15 of top 20
pharma companies served by service portfolio *

Top 28
Products within portfolio***

* Numbers for FY23, ** 2023 Ranking by Science Magazine, *** As per IQVIA MIDAS Oct'22 MAT, top 50 molecules by revenue

Biocon: One Company, with multiple value propositions across its verticals

**From pipeline to production, from drug discovery to drug delivery,
we bring differentiated, high-quality & affordable healthcare products & services, globally**



Generics

Ensuring access through quality, affordability, reliability

- Leadership in fermentation-based APIs – Immunosuppressants, statins, anti-infectives
- Serving 750+ API customers with 50+ APIs from our global scale API facilities
- Expanding portfolio in peptides, high potent and synthetic APIs
- Evolving as a vertically integrated player in complex generic formulations

Biosimilars

Leading vertically integrated global biosimilars company

- Invested >$1B in the development and manufacturing of biosimilars ahead of its peers
- End-to-end capabilities spanning R&D, manufacturing and commercialization in Advanced & Emerging Markets
- Committed to enabling affordable access with global reach in 100+ countries
- Achieved several global “firsts”, setting new benchmarks for the industry
- Comprehensive industry leading portfolio of 20 biosimilars targeting an attractive ~$80B opportunity by FY28

Novels

Pushing scientific boundaries to deliver impactful innovations

- Differentiated pipeline in immunology with expansions into new indications
- Bicara addressing unmet need in oncology through precision immunotherapy with BCA 101

Research Services

Syngene - partnering to deliver innovative scientific solutions

- A global CRO and CDMO offering integrated solutions across discovery research, development and manufacturing including commercial supplies for both small and large molecules
- Scientific services spanning multiple therapeutic areas, modalities and industry segments
- Working with 400+ clients and collaborated with 13 of the top 15 pharmaceutical companies
- Operating to global quality standards from 2 Mn sq. ft. R&D and manufacturing infrastructure in Bengaluru, Mangaluru, and Hyderabad

Generics Business at a Glance

Presence in
100+
countries including U.S., Europe & large EMs

7
State-of-the-art manufacturing sites

90+
cGMP approvals received from international regulatory agencies

R&D team of
500+
Scientists & Postgraduates

750+
Global customer reach

Portfolio comprises
50+ APIs
75+ Generic formulations

100+
Generic formulation dossiers submitted

500+
DMFs filed in various jurisdictions

300+
patents obtained

Note: Status as of September 2023

Generics : API & Formulations - Growth Levers

Strengths built over the years

- Expertise in fermentation technology, large scale chromatography & synthetic chemistry
- Leveraging in-house API to forward integrate and move up the value chain
- Balanced portfolio across therapeutic segments

Product Portfolio Expansion

- API - Expanding portfolio beyond fermentation and synthetic molecules to peptides, high potent APIs
- Formulations – Complex injectables, device dependent products, potent oral solids, modified-release and extended-release oral solids
- Augmenting portfolio through in-licensing strategy

Capacities Additions & Expansion

- Immunosuppressants API (Visakhapatnam)
- Other Fermentation APIs (Bengaluru)
- Peptides (Bengaluru)
- Synthetic API (Hyderabad)
- Injectables (Bengaluru)
- Acquisition of oral solid manufacturing facility (US)

Business Development initiatives

- Strategic partnerships with key customers
- Local manufacturing mandate opportunities in global markets - Technology transfer/ API supply / finished dosage formulations
- API: Expansion of business in key markets
- Formulations: Expand commercial footprint beyond U.S, either directly or through partners

Other initiatives

- Continued focus on cost improvement and quality compliance
- De-risk critical intermediates sources
- Digital transformation to support key strategic priorities
- Focus on ESG initiatives like use of renewable energy, promoting gender diversity (incl. women on the shop-floor)

Generics : Our Key APIs and Formulations

APIs*

Therapeutic Area	Molecule
Cardiovascular	Apixaban
	Atorvastatin
	Dabigatran
	Fluvastatin
	Ivabradine
	Pravastatin
	Rivaroxaban
	Rosuvastatin
	Simvastatin
	Lovastatin
	Sacubitril
Anti-Diabetics	Liraglutide
	Dapagliflozin
	Empagliflozin
	Linagliptin
	Repaglinide
	Sitagliptin
	Vildagliptin
	Pioglitazone

Therapeutic Area	Molecule
Immunosuppressants	Tacrolimus
	Mycophenolate Mofetil
	Mycophenolate Sodium
	Everolimus
	Sirolimus
	Pimecrolimus
Oncology	Dasatinib
	Everolimus
	Lenalidomide
	Temsirolimus
	Cabozantinib
Anti-fungal	Micafungin
	Anidulafungin
	Posaconazole
Multiple Sclerosis	Fingolimod
	Teriflunomide
Others	Orlistat
	Deferasirox
	Brinzolamide
	Mirabegron
	Fidaxomicin

FORMULATIONS

Therapeutic Area	Molecule	US	Dev. Markets: ex-US	MoW[1]
Cardiovascular	Rosuvastatin Calcium		EU	
	Simvastatin			
	Atorvastatin			
	Pravastatin			
	Labetalol HCl			
	Prazosin			
Oncology	Everolimus		EU[$]	
	Pemetrexed	TA		
	Lenalidomide	TA	EU[$]	
Immunosuppressants	Tacrolimus			
	Mycophenolic Sodium			
Multiple Sclerosis	Fingolimod			
	Teriflunomide			
Others	Aminocaproic acid (Antifibrinolytic)			
	Dapagliflozin (Anti Diabetic)	TA		
	Esomeprazole DR (Gastrointestinal)			
	Dorzolamide (Ophthalmic)			
	Posaconazole (Anti-Fungal)		UK, EU[$]	
	Famotidine (Gastrointestinal)			
	Vigabatrin Oral Solution (CNS)			
	Vigabatrin Tablets (CNS)			

Launched *Approved*

** Filed DMFs | 1 MoW - Most of the World markets | [$]Select EU countries | TA – Tentative approval*

Biosimilars Business at a Glance

Global reach in
100+
countries including U.S., Europe and EMs

Top 15
in global biomanufacturing capacity

85+
cGMP approvals received from key regulatory agencies

Diverse global talent pool of
5,500+
people

390+
patents granted

Portfolio comprises
20 biosimilars

8
Commercial Products in Global Markets

5.5M+
Patients served

Unique, fully integrated leading global biosimilars player

Biosimilars: Unique, fully integrated capabilities from lab to market

Research & Development

- Process & Product Development
- Analytical & Bioanalytical Capabilities
- Pre-clinical & Clinical Development
- Intellectual Property
- Regulatory Sciences

Global Scale Manufacturing

- Mammalian & microbial tech platforms
- 3 Manufacturing Sites
- Drug Substance, Drug Product & Devices Capabilities for insulins & mAbs
- 85+ cGMP Approvals (including U.S. FDA & EMA)

Commercialization

- Commercial footprint in 100+ countries
- 8[1] products commercialized globally
- Hybrid model: Direct presence + Network of partners & distributors

[1]Two products are in-licensed i.e. Adalimumab & Etanercept

Biosimilars: Leading global player with a strong track record of success

Built on a 40+ year legacy of cutting-edge science

- **Invested >$1B in biosimilars ahead of its peers** to build expertise across multiple platforms and a differentiated portfolio - including insulins, mAbs and fusion proteins
- **In-house R&D, clinical and regulatory capabilities** to develop high precision biosimilars for global markets
- **Expertise in large scale manufacturing,** across Drug Substance, Drug Product and Devices and among the **Top 15 globally** in biomanufacturing **capacity**
- **Commercial reach in 100+ markets** through a combination of direct presence[1], strategic partnerships and distributors

…with a strong track record in an attractive market

- **Achieved many 'firsts' in the industry** - first to receive bTrastuzumab, bPegfilgrastim and interchangeable bGlargine approval in the US
- **Commercialized products in key Advanced Markets,** such as the US, EU, Japan and **several Emerging Markets** (e.g., India, Brazil, UAE, etc.)
- **Backed by marquee investors** including Tata Capital, True North, Goldman Sachs, ADQ, Viatris, Serum and Edelweiss
- Biosimilars are an **attractive market** with FY22 addressable of $25B[2], growing to ~**$80B in FY28[2]**

Committed to enabling affordable access to high quality biosimilars globally

1 Through the acquisition of Viatris' biosimilars business | 2 Only includes products where there has been company reported sales; Biosimilar sales only included for companies that report the numbers

Biosimilars: Acquisition of Viatris' global biosimilars business

Accelerates BBL's direct entry in many markets across AMs & EMs, takes us closer to patients

Provides full ownership of collaboration assets, as well as Viatris' rights for in-licensed biosimilars

Creates a unique, fully integrated, global biosimilars enterprise

Recognition of combined revenue and associated profits from acquired business kicks in



Leveraging **THE POWER OF ONE**
Enabling Affordable Access to Life-saving Biosimilars, Worldwide

USD 3B+ Acquisition - Amongst Largest Deals in Indian Pharma Industry

- **Builds on a decade-long strategic partnership with Viatris**
- **Transforms Biocon Biologics into leading global player**

Transformational deal to create value for all stakeholders

AMs: Advanced Markets | EMs: Emerging Markets

Biosimilars: Comprehensive, industry leading portfolio of 20 biosimilars

Therapy Area	Oncology	Immunology	Ophthalmology	Bone Health	Diabetes	Others
Approved or Commercial	• Pegfilgrastim • Trastuzumab • Bevacizumab	• Adalimumab • Etanercept	• Aflibercept		• RHI • Glargine U100 • Aspart	
Late Stage[1]	• Denosumab • Pertuzumab	• Ustekinumab		• Denosumab		
Early Stage[2]	2 undisclosed assets	3 undisclosed assets			• Glargine U300	2 undisclosed assets

New product launches planned almost every year through 2030

1. Clinical to BLA Review; 2. Pre-Clinical

Novel Molecules: Itolizumab

Pushing to deliver impactful innovations in collaboration with Equillium Inc.

Itolizumab

World's first novel humanized anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM pathway

Biocon's second global 'lab to market' novel biologic after Nimotuzumab

Launched in India in 2013 to treat chronic plaque psoriasis under the brand ALZUMAb™

Licensed out rights to develop & commercialize in the U.S., Canada, Australia and New Zealand to U.S.-based biotechnology company, Equillium Inc. in 2017

Option and Purchase Agreement entered between Equillium and Ono Pharmaceutical Co., Ltd, Japan, where Equillium has granted Ono the exclusive right to acquire its rights to itolizumab

Acute Graft-Versus-Host Disease (aGVHD)	✓ Pivotal Phase III Study initiated in Apr '22 for use in First-Line treatment of aGVHD; enrollment ongoing ✓ Received US FDA Fast Track & Orphan Drug Designations ✓ European Commission granted Orphan Drug Designation
Systemic Lupus Erythematosus/ Lupus Nephritis (SLE/LN)	✓ Received Fast Track designation from the US FDA ✓ Given positive trends in Part A, expanded Part B portion of Phase 1b EQUALISE study to clinical centers in India ✓ Patient enrolment complete for the LN study ✓ Topline data expected early in 2024
Cytokine Release Syndrome treatment in 'Moderate to Severe' Acute Respiratory Distress Syndrome	✓ Repurposed for prevention & treatment of COVID-19 complications in India in 2020 ✓ Granted 'Restricted Emergency Use' approval in Sep '20
Ulcerative Colitis	✓ Initiated Phase 2 clinical study of Itolizumab in patients with Ulcerative Colitis in Dec '22

Novel Molecules: Bicara Therapeutics* - Dual Action | Dual Impact

The precision of targeted therapies | The power of tumor modulators

BCA101

(Formerly FmAb2)

Lead candidate

First-in-class EGFR / TGFβ-trap bifunctional antibody

BCA 101

- ✓ Lead product candidate, **BCA101** (EGFR / TGF-β-trap) demonstrates tumor target engagement and clinical activity
- ✓ BCA101 + pembrolizumab combination dose expansion study **in 1L HNSCC demonstrates significant improvement over standard of care**
  - ✓ In Ph 1 HNSCC trials, BCA101 **demonstrated a strong clinical profile, including an ORR of 57%, CR rate of 18%, mPFS of at least 6.2mos**, and a well-tolerated safety profile
- ✓ Strong scientific rationale supports BCA101's applicability beyond HNSCC, including sqNSCLC, squamous esophageal, and others

Organization

- ✓ Highly experienced management team, board of directors and advisory board
  - ✓ Expanded Board with recent additions of Kate Haviland, CEO Blueprint Medicines and Scott Robertson, CFO Dice Therapeutics
- ✓ $190M raised to date from syndicate of dedicated biotech investors. Biocon ownership at 38%, to reduce to ~23% in FY24.
- ✓ Leveraging the Biocon and Syngene infrastructure to offer agility and deep experience in CMC/drug development

**a US based clinical-stage biotechnology company. In Q4FY21, Biocon ceded control over the Board of Directors and Operations of Bicara to enable it to operate independently under a US based leadership team and raise funds to advance its development programs. As a result of this change, Bicara was classified as an Associate from a Subsidiary under IND-AS.*

Syngene's broad capabilities, spanning the value chain, facilitate integration to captures additional benefits for clients

Research business

Discovery Services

Flexible Platform with capability across multiple modalities including small molecule, large molecule, peptides, oligonucleotides, antibody drug conjugates, PROTACs

SynVent - our proprietary platform for Integrated Drug Discovery

SARchitect- our proprietary platform for data visualization and analysis, including features specifically designed to foster collaboration between scientific experts across geographies

Dedicated R&D Centers

Ring-fenced infrastructure for exclusive operations for an individual client

Dedicated, multi-disciplinary team of scientists

Access to entire Syngene ecosystem for specialist research and development operations

Development and Manufacturing business

Development Services

Pre-clinical to clinical trials

Drug substance and drug product development

Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate

cGMP-compliant manufacturing of clinical supplies, and registration batches for small molecules

Manufacturing Services

Manufacturing of small and large molecules for commercial supplies

cGMP-compliant facilities

State-of-the art API manufacturing and Biologics manufacturing facilities

Syngene: Strategic Priorities

Research: Discovery Services

Provide end-to-end therapeutic discovery capabilities including differentiating research technologies and platforms, across many disciplines, disease areas and therapeutic modalities

Research: Dedicated Centers

Continue to strengthen our existing partnerships with Amgen, Bristol Myers Squibb (BMS) and Baxter through the dedicated centers which provide: a strong foundation for future planning; revenue visibility over the medium to long term; and predictable cash flows

Operational Excellence

Focus on customer delivery through operational excellence

Development and Manufacturing Services – Small Molecules

Leverage existing capabilities to offer integrated Chemistry, Manufacturing, and Controls (CMC) solutions

Secure U.S. FDA and other major global regulatory approvals for the small molecule commercial scale manufacturing facility as a platform to attract a broader scope of projects

Development and Manufacturing Services – Large Molecules

Drive an integrated approach for biologics development and manufacturing to provide a one-stop-shop capability from drug discovery to commercial manufacturing for biologics

Accelerate capacity build-up

People

Develop strong leaders and managers while offering all employees career- long learning opportunities

Environmental, Social and Governance (ESG)

Committed to operating in a responsible and sustainable manner.

Q2 FY24 Highlights

Financial Highlights: Q2 FY24

Consolidated (in ₹ Cr.)	Q2 FY24	Q2 FY23	YoY %	
Total Revenue	**3,620**	2,384	52	**Biosimilars +97% | Research +18% | Generics +4%**
Core EBITDA[1]	**1,100**	815	35	Growth across Generics, Biosimilars & Research Services
% Margin	*32%*	*35%*		
EBITDA	**900**	535	68	**Net R&D spend** at ₹264 Cr, up ₹22 Cr vs Q2 FY23, representing 10% of revenues ex-Syngene
% Margin	*25%*	*22%*		
Profit Before Tax *(Before exceptional charge)*	**238**	246	(3)	**Increase in depreciation, amortization and interest expense by ₹376 Cr**, primarily related to acquisition of Viatris' biosimilar business
% Margin	*7%*	*10%*		
Net Profit *(Before exceptional charge)*	**142**	168	(16)	**Increase in minority interest** due to dilution of shareholding in Syngene and Biocon Biologics on account of the Viatris deal
Net Profit Margin %	***4%***	*7%*		

[1] Core EBITDA defined as EBITDA before forex, dilution gain in Bicara, R&D, licensing income and mark to market movement on investments.

Financial Highlights: Q2 FY24

Consolidated (in ₹ Cr.)	Q2 FY24	Q2 FY23	YoY %
Net Profit *(before exceptional charge)*	**142**	168	(16)
Exceptional Items *(net of tax and minority interest)*	(16)	(122)	
Net Profit *(Reported)*	**126**	47	168

Exceptional items:

- **Q2 FY24**
  - PLI accrual reversal for last year
  - Stelis acquisition related expenses
- **Q2 FY23**
  - Deal related expenses of the Viatris transaction
  - MAT credit balance charge on adoption of new tax regime of 25%

Biocon Generics: Q2 FY24 Highlights

- Performance driven by continued traction in our US generic formulations business and expansion in MoW markets. API business performance muted.
- Announced a partnership agreement with Juno Pharmaceuticals for the commercialization of Liraglutide in Canada
- Acquired U.S. FDA approved oral solid dosage facility of Eywa Pharma Inc.
- Received seven generic formulations approvals across markets. Two API approvals each, received in the U.S. and EU
- Process validation at the Company's greenfield immunosuppressant API facility in Visakhapatnam successfully completed
- Expect sustained performance from the generic formulations and some recovery in API business performance

In ₹ Cr	Q2 FY24	Q2 FY23	YoY %
Segment Revenue	676	652	4
PBT	66	54	22
% of revenue	10	8	

Biocon Biologics: Biosimilars – Q2 FY24 Business Update

- Integrated North America business – seamless commercial operations from 1st September; remain on track to transition Europe, JANZ and the remaining Emerging Markets later during the year
- Good momentum across oncology and insulins; Addition of new customers enables volume growth, accommodating for price erosion
- bAdalimumab (US): adoption of biosimilars slower than anticipated across the market
- Potential to improve EU performance with the completion of transition
- Divesting non-core Dermatology and Nephrology business in India, sharpening focus and aligning it with our global portfolio and strategy

Key Products' Market Share[1]

United States

	Sep-23	Jun-23	Sep-22
Fulphila (bPegfilgrastim)	19%	16%	11%
Ogivri (bTrastuzumab)	12%	11%	10%
Semglee (bGlargine)[2]	11%	12%	9%

Europe

	Jul-23	May-23	Jul-22
Fulphila (bPegfilgrastim)	8%	7%	5%
Ogivri (bTrastuzumab)	4%	5%	5%
Abvemy (bBevacizumab)	7%	5%	1%
Semglee (bGlargine)	2%	2%	1%
Hulio (bAdalimumab)	6%	6%	6%
Nepexto (bEtanercept)	2%	1%	1%

1. Market shares based on IQVIA volumes, Eq.SU I 2. Includes both Semglee and unbranded Glargine

Biocon Biologics: Biosimilars – Q2 FY24 Financial Update

- Revenues marginally down despite significantly lower licensing revenues versus last quarter
- Excluding licensing revenues, sequential growth at 6%, reflecting underlying positive performance of commercial products
- Core EBITDA[1] margin in line with guidance of mid-30s; R&D at 11% of revenue
- Sequential increase of ₹35 Cr in D&A and interest expense

In ₹ Cr	Q2 FY24	Q1 FY24	QoQ %
Revenue	1,969	2,015	(2)
Core EBITDA[1]	660	513	29
% of revenue	34	28	
EBITDA	453	457	(1)
% of Revenue	23	23	
PBT	(15)	24	(164)
% of Revenue	(1)	1	

1. EBITDA before R&D, licensing income, forex and mark-to-market movement on investments

Biocon Biologics: Biosimilars – Q2 FY24 Other Business Updates

- European Commission granted MA for Yesafili (bAflibercept): EU brand sales of ~$1.8 billion annually
- US FDA has issued a CRL for the BLA of our Insulin Aspart

Key Catalysts

- Activation of near-term catalysts: bAdalimumab, bAspart and bBevacizumab
- Future growth catalysts: bAflibercept, bUstekinumab, bDenosumab (total originator sales of $25 billion)

1. EBITDA before R&D, licensing income, forex and mark-to-market movement on investments

Novels : Q2 FY24 Update

Itolizumab *(partnered with Equillium)*

- Patient enrolment ramped up in the pivotal Phase III clinical study of itolizumab in patients with aGVHD* (EQUATOR study)
- Pivotal Phase 1b clinical study of Itolizumab for Lupus Nephritis (EQUALISE study) fully enrolled. Topline data expected early in 2024.

*Acute Graft-Versus-Host Disease

BCA101 *(Bicara[$])*

- Bicara recently presented updated, positive interim data from its ongoing, open-label Phase 1/1b dose expansion study of BCA101 in European Society for Medical Oncology (ESMO) Congress; strong investigator interest to enroll patients in future studies
- $108 million Series B Financing from dedicated biotech investors is being realized in a staggered manner; Biocon recorded a step-up gain of ₹75 crores in the consolidated P&L statement during the quarter

[$]a US based clinical-stage biotechnology company. In Q4FY21, Biocon ceded control over the Board of Directors and Operations of Bicara to enable it to operate independently under a US based leadership team and raise funds to advance its development programs. As a result of this change, Bicara was classified as an Associate from a Subsidiary under IND-AS.

Syngene: Q2 FY24 Update

- Strong performance led by Development and Manufacturing Services; supported by sustained momentum in Dedicated Centers
- In Manufacturing Services, Syngene continued to make good progress on the long-term biologics manufacturing partnership with Zoetis

In ₹ Cr	Q2 FY24	Q2 FY23	YoY %
Revenue	910	768	18
EBITDA	276	232	19
% of Revenue	30	30	
PBT	158	130	22
% of revenue	17%	17%	

Environment, Social, Governance

ESG: A Culture of Purpose, Ethics & Equity

Going beyond financials to have a positive impact

Our ESG Strategy Pillars

- Improve access to high quality therapeutics to drive ‘Patient Equity’
- Build an empowering and inclusive workplace creating ‘People Equity’
- Adapting to a sustainable business operations for ‘Environment Equity’
- Operate with integrity, transparency and accountability ensuring ‘Stakeholder Equity’
- Enable underserved communities ‘Social Equity’

Monitor Performance → Improve Through Initiatives → Report Outcomes

Disclosures and Recognitions

- *Published 1st GRI aligned Integrated Report & 2nd BRSR Report for FY23*
- *Improved ESG score of 52, part of Emerging Markets Index & 2023 Sustainability Yearbook*
- *Maintained score of ‘B’ in 2022 for Water Security*
- *Secured ‘Silver’ place and improved score to 66 in 2022.*
- *Ranked #8 by Science Magazine – Top Global Pharma & Biotech Employers in 2023*
- Top 10 - India’s Best Workplaces in Diversity, Equity and Inclusion, 2021
- Won ET Edge Employee Excellence Award , 2023

Progressed to Integrated Reporting

Continuously improving disclosures towards better transparency



1st GRI aligned Integrated Report for FY23 with many maiden disclosures

- Outcome of Gender Pay Gap Analysis
- Alignment with TCFD
- Outcome of Water Risk Assessment
- Outcome of Biodiversity Impact Assessment
- Third Party Assurance of EHS data
- Alignment with UNGC Principles
- BRSR (voluntarily adopted in FY22)

Annexures

Our Evolution Over the Years



	FY1999	FY2004	FY2009	FY2015	FY2018	FY2022	FY2023
PEOPLE	250+	700+	3,500+	7,500+	10,000+	15,000+	16,500+
REVENUE	$5 Mn	$85 Mn	$184 Mn	$484 Mn	$667 Mn	$1.1 Bn	$1.4 Bn

1 USD = ₹82.21 for FY23

With many firsts, Biocon is ahead of the curve



Safe Harbor Statement

This release may include statements of future expectations and other forward-looking statements based on management's current expectations and beliefs concerning future developments and their potential effects upon Biocon and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance, or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst other: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition in and the conditions of the Indian and global biotechnology and pharmaceuticals industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Biocon, nor our directors, or any of our subsidiaries/associates assume any obligation to update any particular forward-looking statement contained in this release.

Thank You

Relentless Pursuit.
Differentiated Growth.